Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gersizangitide
- Development stage
- Phase 2
- Lead developer
- AsclepiX Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Peptides
- Administration
- Intraocular
01
Overview
Gersizangitide (AXT107) is a novel therapeutic peptide and angiogenesis inhibitor developed by AsclepiX Therapeutics for the treatment of ophthalmic conditions such as neovascular (wet) age-related macular degeneration (nAMD), diabetic macular oedema, and retinal vein occlusion. It acts through a dual mechanism of action by inhibiting pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activating the vessel-stabilizing TIE-2 receptor. Gersizangitide also inhibits vascular endothelial growth factor A and C, reduces vascular permeability, suppresses vascular inflammation, and is designed to provide sustained biological activity with a single intraocular injection as a microparticulate suspension[1][5][9]. The peptide sequence is LRRFSTAPFAFIDINDVINF-NH2[4].
- Other names
- gersizangitide2417491-82-6UNII-XBL53GSJ6YUNII-XBL-53GSJ6YUNII-XBL 53GSJ6Y
02
Targets
NeuraminidaseTEK (Tie2)VEGFA (Vascular endothelial growth factor A)VEGFC (VEGF-C)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on gersizangitide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gersizangitide.